Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before and after steroid therapy may help doctors assess a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase I trial is studying fludeoxyglucose F 18 PET scan performed before and after ultra short-term dexamethasone therapy to see how well it measures changes in nodules in patients with lung nodules.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Barbara Ann Karmanos Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Fluorodeoxyglucose F18

Criteria

DISEASE CHARACTERISTICS:

• Presence of ≥ 1 measurable pulmonary nodule (1.0-3.0 cm) suggestive of malignancy or chronic inflammatory process on positron emission tomography (PET) scan

• No lesions consistent with malignancy or inflammation according to history, PET findings, or biopsy

• Baseline scan average time between injection and start of scan within 50-70 min

• Mean liver standardized uptake value (SUV) of baseline scan normal

• No sign of significant partial paravenous tracer administration in the images of baseline scan

• No lung nodule(s) suggestive of lymphoma

• No lung lesions suggestive of tuberculosis

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Blood glucose levels ≤ 150 mg/100 mL

• Not pregnant or nursing

• Fertile patients must use effective contraception

• Able to tolerate PET/CT imaging

• No history of diabetes

• No poorly controlled hypertension

• No prior malignancy other than basal cell or squamous cell carcinoma of the skin, carcinoma in situ, or other cancer from which the participant has been disease free for < 3 years

• No active malignancy within the past 5 years

PRIOR CONCURRENT THERAPY:

• More than 5 years since prior chemotherapy or radiotherapy

• No concurrent steroids